IRIS
LO COCO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 131.728
AS - Asia 11.535
EU - Europa 9.730
SA - Sud America 1.617
Continente sconosciuto - Info sul continente non disponibili 1.190
AF - Africa 148
OC - Oceania 37
Totale 155.985
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 131.400
SG - Singapore 4.827
CN - Cina 2.264
UA - Ucraina 1.583
HK - Hong Kong 1.564
DE - Germania 1.334
RU - Federazione Russa 1.309
BR - Brasile 1.298
IE - Irlanda 1.085
IT - Italia 1.082
VN - Vietnam 949
FR - Francia 866
PL - Polonia 824
KR - Corea 711
GB - Regno Unito 499
FI - Finlandia 447
SE - Svezia 326
BD - Bangladesh 305
JP - Giappone 241
IN - India 150
CA - Canada 130
MX - Messico 81
AR - Argentina 79
NL - Olanda 77
IQ - Iraq 70
AT - Austria 60
CO - Colombia 56
ID - Indonesia 56
EC - Ecuador 53
TR - Turchia 53
VE - Venezuela 51
ES - Italia 50
ZA - Sudafrica 43
PK - Pakistan 40
BE - Belgio 36
PH - Filippine 36
EU - Europa 35
JM - Giamaica 35
AU - Australia 34
IR - Iran 34
CL - Cile 32
MY - Malesia 29
SA - Arabia Saudita 25
TH - Thailandia 21
CR - Costa Rica 19
MA - Marocco 19
EG - Egitto 18
NP - Nepal 18
PY - Paraguay 17
AE - Emirati Arabi Uniti 16
TN - Tunisia 16
UZ - Uzbekistan 16
UY - Uruguay 15
PT - Portogallo 14
SK - Slovacchia (Repubblica Slovacca) 14
CZ - Repubblica Ceca 13
HN - Honduras 13
KE - Kenya 13
GR - Grecia 12
GT - Guatemala 12
PE - Perù 12
RO - Romania 12
DZ - Algeria 11
LT - Lituania 11
OM - Oman 11
AL - Albania 10
NO - Norvegia 10
SN - Senegal 10
A2 - ???statistics.table.value.countryCode.A2??? 9
CH - Svizzera 9
DO - Repubblica Dominicana 9
HU - Ungheria 9
JO - Giordania 9
KZ - Kazakistan 9
AZ - Azerbaigian 8
IL - Israele 8
LB - Libano 8
TW - Taiwan 8
CY - Cipro 7
KG - Kirghizistan 7
RS - Serbia 6
BG - Bulgaria 5
ET - Etiopia 5
LK - Sri Lanka 5
NI - Nicaragua 5
PR - Porto Rico 5
SY - Repubblica araba siriana 5
BA - Bosnia-Erzegovina 4
DK - Danimarca 4
LA - Repubblica Popolare Democratica del Laos 4
PA - Panama 4
SV - El Salvador 4
AM - Armenia 3
BO - Bolivia 3
BY - Bielorussia 3
EE - Estonia 3
GE - Georgia 3
HR - Croazia 3
KW - Kuwait 3
MD - Moldavia 3
Totale 154.792
Salva come PNG Salva come JPEG
Città #
Woodbridge 40.477
Wilmington 33.247
Houston 30.695
Fairfield 3.702
Ann Arbor 3.125
Singapore 2.853
Chandler 2.033
Ashburn 1.978
Seattle 1.562
San Jose 1.551
Hong Kong 1.542
Cambridge 1.312
Jacksonville 1.168
Dublin 1.054
Dearborn 1.008
Medford 823
Beijing 784
Kraków 771
Council Bluffs 506
Santa Clara 479
New York 452
Lawrence 386
Dallas 330
The Dalles 314
Lauterbourg 284
Moscow 273
Rome 273
Ho Chi Minh City 266
Los Angeles 266
Hanoi 245
Tokyo 202
San Diego 181
Buffalo 150
Milan 133
São Paulo 113
Zhengzhou 110
Hangzhou 103
Mülheim 95
London 91
Helsinki 89
Norwalk 86
Columbus 81
Menlo Park 81
Hefei 71
Chicago 70
Nuremberg 64
Mountain View 62
Redwood City 62
Boardman 61
Guangzhou 61
Verona 61
Redondo Beach 55
Shanghai 54
Da Nang 45
Nanjing 45
Rio de Janeiro 45
Haiphong 44
Brooklyn 42
San Francisco 41
Frankfurt am Main 40
Kunming 39
Munich 38
Toronto 38
Warsaw 37
Atlanta 36
Orem 36
Phoenix 35
Denver 32
Jakarta 32
Brussels 31
Creede 31
Baghdad 30
Montreal 28
Philadelphia 27
Belo Horizonte 25
Falls Church 25
Fuzhou 25
Mumbai 25
Quito 25
Bologna 24
Chennai 24
Curitiba 23
Jinan 22
Kingston 22
San Mateo 22
Chengdu 21
Johannesburg 21
Kuala Lumpur 21
Stockholm 21
Brasília 20
Nanchang 20
North Bergen 20
Seoul 20
University Park 20
Amsterdam 19
Hounslow 19
Indiana 19
Mexico City 19
Porto Alegre 19
Campinas 18
Totale 137.226
Salva come PNG Salva come JPEG
Nome #
Immunophenotyping of acute myeloid leukaemia: relevance of analysing different lineage-associated markers 823
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 642
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel 565
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 563
Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer 538
Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells 533
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia 527
A case of SRSF2 mutation in chronic lymphocytic leukemia 522
A systems medicine clinical platform for understanding and managing non- communicable diseases 519
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 509
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia 505
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 500
Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission 500
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: Final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up 492
Identification of a potential topoisomerase II “hotspot” DNA region in the DEK gene in two t(6;9)-positive therapy-related myeloid neoplasms 492
Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation 491
What is the standard regimen for patients with acute promyelocytic leukemia? 489
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet 488
Infectious complications in patients with acute promyelocytic leukaemia treated with the AIDA regimen 487
A miRNA signature in human cord blood stem and progenitor cells as potential biomarker of specific acute myeloid leukemia subtypes 486
Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells 486
"Composite" lymphoma, lymphoplasmacytoid and diffuse large B-cell lymphoma of the spleen: molecular-genetic evidence of a common clonal origin 485
MiR-21 is overexpressed in NPM1-mutant acute myeloid leukemias 483
Utilization of molecular phenotypes to detect relapse and optimize the management of acute promyelocytic leukemia 477
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 477
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 476
Acute promyelocytic leukemias share cooperative mutations with other myeloid-leukemia subgroups 476
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis 475
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. 474
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 473
Development of a High-Resolution Melting Curve Analysis Screening Test for SRSF2 Splicing Factor Gene Mutations in Myelodysplastic Syndromes 473
Differential hypoxic regulation of the microRNA-146a/CXCR4 pathway in normal and leukemic monocytic cells: Impact on response to chemotherapy 472
Absence of HHV-8 DNA sequences in malignant mesothelioma 472
Treatment of elderly patients (>= 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols 470
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide 469
Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts 468
Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy 468
All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies 467
A systems medicine clinical platform for understanding and managing non- communicable diseases 466
8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes 465
Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. 465
NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype. 464
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 464
Clonal evolution in therapy-related neoplasms 464
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL 462
Cytotoxic effects of high concentrations of sodium ascorbate on human myeloid cell lines 462
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients with Arsenic Trioxide and Retinoic Acid in the United States 461
PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity 461
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 460
Current management of newly diagnosed acute promyelocytic leukemia 460
Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors 460
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation 458
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. 457
GIMEMA-AIEOP AIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children 456
Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia 456
Clustering of genomic breakpoints at the MLL locus in therapy-related acute leukemia with t(4;11)(q21;q23) 456
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis 455
Idiopathic hypereosinophilic syndrome: A case evolving in B-lymphoblastic lymphoma 455
Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients 454
Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease 454
PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy 454
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet 453
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. 451
Imatinib-mesylate for all patients with hypereosinophilic syndrome? 451
Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status 451
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy 450
A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms 450
Podocalyxin is expressed in normal and leukemic monocytes 450
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy 449
High Δnp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia 449
BCL-6 and the molecular pathogenesis of B-cell lymphoma 449
Acute myeloid leukemia developing in patients with autoimmune diseases. 448
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 447
Randomized Phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: Health-related quality-of-life outcomes 447
The hidden genomic landscape of acute myeloid leukemia: Subclonal structure revealed by undetected mutations 447
Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias 445
Panobinostat for the treatment of acute myelogenous leukemia 444
Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. 444
Arsenic trioxide: its use in the treatment of acute promyelocytic leukemia 443
Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: a possible manifestation of retinoic acid syndrome [10] 443
Molecular characterization of Ph' + hybrid acute leukemia 443
NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia 441
Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC 441
In vitro all-trans retinoic acid sensitivity of acute myeloid leukemia blasts with NUP98/RARG fusion gene 440
Characteristics and clinical correlates of MPL 515W > L/K mutation in essential thrombocythemia 439
Current treatment of acute promyelocytic leukemia. 439
Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): a comparison with NPMc+ AML 438
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid 438
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo 437
CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy 437
Genomic variability and alternative splicing generate multiple PML/RAR alpha transcripts that encode aberrant PML proteins and PML/RAR alpha isoforms in acute promyelocytic leukaemia 437
Overexpression of BP1, a homeobox gene, is associated with resistance to all-trans retinoic acid in acute promyelocytic leukemia cells 436
The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia 436
Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men 436
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro 436
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia 435
Argonaute 2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells 435
Time to improve health-related quality of life outcomes in patients with acute promyelocytic leukemia 434
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin's lymphoma: association with diffuse large-cell subtype 434
Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? 434
Totale 47.038
Salva come PNG Salva come JPEG
Categoria #
all - tutte 332.819
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 332.819
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.996 0 0 124 163 94 232 222 185 210 286 404 1.076
2022/20235.059 580 256 188 622 452 1.222 445 357 545 39 246 107
2023/20241.512 230 76 118 35 181 368 33 112 17 32 14 296
2024/20257.317 286 1.980 889 382 80 246 760 411 837 492 491 463
2025/202611.733 906 841 1.597 695 725 351 1.824 1.364 1.645 929 402 454
2026/20271.854 490 614 750 0 0 0 0 0 0 0 0 0
Totale 155.985